Supplement encyclopedia

Choline

Choline is an essential nutrient obtained from food and supplements.

Double-check the conclusions and read the sources before choosing a supplement.

Main conclusion

What it may offer

  • Citicoline at 500 mg a day for 12 weeks may slightly help adults aged 50–85 with memory complaints remember pairs: improvement in a secondary test was 0.15 versus 0.06 points with placebo. No advantage over placebo was found in the primary spatial memory test.
  • In healthy adults aged 18–29, a single 2.5 g dose of choline bitartrate showed no advantage over placebo in three memory tests or self-rated mood and arousal.
  • In adults aged 40–74, lysolecithin providing 480 mg of lysophosphatidylcholine a day for eight weeks showed no advantage over placebo in overall memory, self-rated sleep or calmness.
  • In trained men aged 23–29, a single 2.43 g dose of bitartrate an hour before cycling exercise showed no advantage over a choline-free drink in time to exhaustion or work performed. In another study, 8.425 g of choline citrate before and during a prolonged loaded march showed no advantage over placebo in subsequent running or squats.
  • In young men, α-GPC at 250 or 500 mg a day for seven days showed no advantage over placebo in strength or reaction speed in an attention task.
  • Phosphatidylcholine providing 750 mg of choline a day from week 18 of pregnancy until 90 days after birth showed no advantage over placebo in children's memory, language or overall development at 10–12 months. Mothers obtained about 360 mg of choline a day from food on average.
  • After 9000 mg of phosphatidylcholine a day from week 16 of pregnancy until delivery, parents reported persistent or multiple signs of social withdrawal less often in children aged 18 months to four years than with placebo. This exact pregnancy regimen was studied; 9000 mg is the compound's weight, not pure choline.
  • In the same study, no clear reduction in parent-rated attention problems was found in children aged one and a half to four years. Mothers took 9 000 mg of phosphatidylcholine a day during pregnancy.
  • After the same pregnancy regimen, a secondary IQ measure in 103 children up to four years old was on average 7.78 points higher than with placebo. The possible benefit concerns this child test result in the group studied.

[1] [2] [3] [4] [5] [6] [7] [8]

What was studied

  • Adult memory, mood and sleep were studied in three publications on bitartrate, lysolecithin and citicoline; different tests in one paper concern the same participants, not separate independent studies. This helps assess the amount of evidence when choosing a supplement.
  • Three more publications concern exercise with bitartrate, choline citrate or α-GPC, and two concern children's development after phosphatidylcholine during pregnancy. The specific form and participant group described beside the result matter when choosing.

[1] [2] [3] [4] [5] [6] [7] [8]

Which forms were considered

  • Studies considered bitartrate, choline citrate, phosphatidylcholine, lysolecithin, citicoline and α-GPC: check the form's name on the packaging when choosing.
  • Compare the amount of choline itself and the compound's weight on the label: these are different quantities.

[1] [2] [3] [4] [5] [6] [7] [8] [9]

How to get it from food

  • Choline is found in eggs, meat, fish, dairy products and legumes.
  • One large boiled egg provides about 147 mg of choline, and half a cup of roasted soybeans about 107 mg.

[1]

Effects and studied questions

How to read the certainty scale 1–4

Certainty is rated separately for each outcome. 1 is very low, 2 is low, 3 is moderate and 4 is high.

Goal or questionResultConfidenceStudiesPopulation studiedKey sources
Spatial working memoryA single dose of choline bitartrate showed no advantage in spatial working memory.Bitartrate 70±18% versus 72±16%, p=0.630; no advantage found.
2/4 LowPrecision of the estimate: Small sample and no CI of the difference. Consistency of results: No comparable independent series for this outcome and comparison. Applicability to the stated group: The comparison directly answers the stated study question. Possible publication bias: No data for a separate downgrade. Study methods: Minor attrition and limited description of analytical procedures.
11 trialNo Acute Effects of Choline Bitartrate Food Supplements on Memory in Healthy, Young, Human Adults ↗Healthy adults aged 18–29, 40 started experiment 3, 37 completed
  1. No Acute Effects of Choline Bitartrate Food Supplements on Memory in Healthy, Young, Human Adults ↗
Declarative recallA single dose of choline bitartrate showed no advantage in declarative recall.Bitartrate 71±15% versus 72±11%, p=0.489; no advantage found.
2/4 LowPrecision of the estimate: Small sample and no CI of the difference. Consistency of results: No comparable independent series for this outcome and comparison. Applicability to the stated group: The comparison directly answers the stated study question. Possible publication bias: No data for a separate downgrade. Study methods: Minor attrition and limited description of analytical procedures.
11 trialNo Acute Effects of Choline Bitartrate Food Supplements on Memory in Healthy, Young, Human Adults ↗Healthy adults aged 18–29, 40 started experiment 3, 37 completed
  1. No Acute Effects of Choline Bitartrate Food Supplements on Memory in Healthy, Young, Human Adults ↗
Verbal working memoryA single dose of choline bitartrate showed no advantage in verbal working memory.Bitartrate 35±20 versus 35±19, p=0.987; no advantage found.
2/4 LowPrecision of the estimate: Small sample and no CI of the difference. Consistency of results: No comparable independent series for this outcome and comparison. Applicability to the stated group: The comparison directly answers the stated study question. Possible publication bias: No data for a separate downgrade. Study methods: Minor attrition and limited description of analytical procedures.
11 trialNo Acute Effects of Choline Bitartrate Food Supplements on Memory in Healthy, Young, Human Adults ↗Healthy adults aged 18–29, 40 started experiment 3, 37 completed
  1. No Acute Effects of Choline Bitartrate Food Supplements on Memory in Healthy, Young, Human Adults ↗

The study count refers to the cited source. Reviews with overlapping trials and outcomes from one study are not added together.

Daily intake requirements and upper limits

Intake and studied regimens
ContextInformation
Intake referencesAdequate total choline intake (AI) for adults: 550 mg/day for men, 425 mg for women, 450 mg during pregnancy and 550 mg during lactation. This combines food and supplemental choline, not a prescribed supplement dose.

NIH ODS Choline Fact Sheet for Health Professionals ↗

Forms

Choline is an essential nutrient. Bitartrate, phosphatidylcholine, lysolecithin, citicoline and α-GPC differ in composition and elemental choline dose; results from one form do not transfer to another. Distinguish the salt or compound's weight from the amount of choline itself on the label: these are different quantities.

Guidance for each goal

Spatial working memory2/4 LowRead moreCollapse
Confidence
2/4 LowPrecision of the estimate: Small sample and no CI of the difference. Consistency of results: No comparable independent series for this outcome and comparison. Applicability to the stated group: The comparison directly answers the stated study question. Possible publication bias: No data for a separate downgrade. Study methods: Minor attrition and limited description of analytical procedures.

A single dose of choline bitartrate showed no advantage in spatial working memory.

Study findings. A single dose of choline bitartrate showed no advantage in spatial working memory.

Studied regimenOral choline bitartrate 2.5 g (about 1 g of choline) in 400 ml of orange juiceOral choline bitartrate 2.5 g (about 1 g of choline) in 400 ml of orange juice
Duration and populationSingle dose in each phase, 1-week intervalHealthy adults aged 18–29, 40 started experiment 3, 37 completed

Comparison: Placebo

Declarative recall2/4 LowRead moreCollapse
Confidence
2/4 LowPrecision of the estimate: Small sample and no CI of the difference. Consistency of results: No comparable independent series for this outcome and comparison. Applicability to the stated group: The comparison directly answers the stated study question. Possible publication bias: No data for a separate downgrade. Study methods: Minor attrition and limited description of analytical procedures.

A single dose of choline bitartrate showed no advantage in declarative recall.

Study findings. A single dose of choline bitartrate showed no advantage in declarative recall.

Studied regimenOral choline bitartrate 2.5 g (about 1 g of choline) in 400 ml of orange juiceOral choline bitartrate 2.5 g (about 1 g of choline) in 400 ml of orange juice
Duration and populationSingle dose in each phase, 1-week intervalHealthy adults aged 18–29, 40 started experiment 3, 37 completed

Comparison: Placebo

Verbal working memory2/4 LowRead moreCollapse
Confidence
2/4 LowPrecision of the estimate: Small sample and no CI of the difference. Consistency of results: No comparable independent series for this outcome and comparison. Applicability to the stated group: The comparison directly answers the stated study question. Possible publication bias: No data for a separate downgrade. Study methods: Minor attrition and limited description of analytical procedures.

A single dose of choline bitartrate showed no advantage in verbal working memory.

Study findings. A single dose of choline bitartrate showed no advantage in verbal working memory.

Studied regimenOral choline bitartrate 2.5 g (about 1 g of choline) in 400 ml of orange juiceOral choline bitartrate 2.5 g (about 1 g of choline) in 400 ml of orange juice
Duration and populationSingle dose in each phase, 1-week intervalHealthy adults aged 18–29, 40 started experiment 3, 37 completed

Comparison: Placebo

Overall WMS-R memory2/4 LowRead moreCollapse
Confidence
2/4 LowPrecision of the estimate: 45 analysed and no CI of the effect. Consistency of results: No comparable independent series for this outcome and comparison. Applicability to the stated group: The comparison directly answers the stated study question. Possible publication bias: No data for a separate downgrade. Study methods: Marked baseline memory imbalance complicates assessment of changes.

Lysolecithin showed no advantage in overall memory over eight weeks.

Study findings. Lysolecithin showed no advantage in overall memory over eight weeks.

Studied regimenOral lysolecithin, 480 mg of lysophosphatidylcholine a dayOral lysolecithin, 480 mg of lysophosphatidylcholine a day
Duration and population8 weeks46 adults aged 40–74, analysis 23 and 22

Comparison: Placebo

Primary Spatial Span / Monkey Ladder2/4 LowRead moreCollapse
Confidence
2/4 LowPrecision of the estimate: One RCT, CI of the contrast not provided in the extraction. Consistency of results: No comparable independent series for this outcome and comparison. Applicability to the stated group: The comparison directly answers the stated study question. Possible publication bias: No data for a separate downgrade. Study methods: Industry funding and incomplete quantitative reporting of the primary contrast.

Citicoline showed no advantage in the primary spatial memory test over 12 weeks.

Study findings. Citicoline showed no advantage in the primary spatial memory test over 12 weeks.

Studied regimenOral citicoline 500 mg/dayOral citicoline 500 mg/day
Duration and population12 weeks100 adults aged 50–85 with age-related memory complaints, 99 completed

Comparison: Placebo

Secondary Paired Associates, episodic memory1/4 Very lowRead moreCollapse
Confidence
1/4 Very lowPrecision of the estimate: One RCT without an exact contrast CI in the extraction. Consistency of results: No comparable independent series for this outcome and comparison. Applicability to the stated group: The laboratory test does not measure preservation of everyday function. Possible publication bias: No data for a separate downgrade. Study methods: Secondary result in a test battery.

In the secondary episodic memory test, the score improved by 0.15 versus 0.06 points with placebo.

Study findings. In the secondary episodic memory test, the score improved by 0.15 versus 0.06 points with placebo.

Studied regimenOral citicoline 500 mg/dayOral citicoline 500 mg/day
Duration and population12 weeks100 adults aged 50–85 with age-related memory complaints, 99 completed

Comparison: Placebo

Time to exhaustion2/4 LowRead moreCollapse
Confidence
2/4 LowPrecision of the estimate: Two groups of 10 and CI not extracted. Consistency of results: No comparable independent series for this outcome and comparison. Applicability to the stated group: The comparison directly answers the stated study question. Possible publication bias: No data for a separate downgrade. Study methods: Available reporting insufficient to assess concealment and analysis.

Time to exhaustion did not differ significantly in the two cycling exercise protocols.

Study findings. Time to exhaustion did not differ significantly in the two cycling exercise protocols.

Studied regimenOral choline bitartrate 2.43 g in a drinkOral choline bitartrate 2.43 g in a drink
Duration and populationSingle dose 1 hour beforehand, crossover protocol20 trained men aged 23–29, 10 each at 150% and 70% VO₂max

Comparison: The same drink without choline

Work performed2/4 LowRead moreCollapse
Confidence
2/4 LowPrecision of the estimate: Two groups of 10 and CI not extracted. Consistency of results: No comparable independent series for this outcome and comparison. Applicability to the stated group: The comparison directly answers the stated study question. Possible publication bias: No data for a separate downgrade. Study methods: Available reporting insufficient to assess concealment and analysis.

Work performed did not differ significantly in the two cycling exercise protocols.

Study findings. Work performed did not differ significantly in the two cycling exercise protocols.

Studied regimenOral choline bitartrate 2.43 g in a drinkOral choline bitartrate 2.43 g in a drink
Duration and populationSingle dose 1 hour beforehand, crossover protocol20 trained men aged 23–29, 10 each at 150% and 70% VO₂max

Comparison: The same drink without choline

Running to fatigue after the march1/4 Very lowRead moreCollapse
Confidence
1/4 Very lowPrecision of the estimate: 14 participants, CI not extracted. Consistency of results: No comparable independent series for this outcome and comparison. Applicability to the stated group: A specific heavily loaded march. Possible publication bias: No data for a separate downgrade. Study methods: Full dosing regimen and analysis unavailable in the abstract.

No advantage in running to exhaustion after the march was found.

Study findings. No advantage in running to exhaustion after the march was found.

Studied regimenOral choline citrate, 8.425 g as described by the source, before and during exerciseOral choline citrate, 8.425 g as described by the source, before and during exercise
Duration and populationOne march in each phase14 participants, 4 h walking at 5.6 km/h with a 34.1 kg load, 3% incline

Comparison: Placebo in a crossover protocol

Squats after the march1/4 Very lowRead moreCollapse
Confidence
1/4 Very lowPrecision of the estimate: 14 participants, CI not extracted. Consistency of results: No comparable independent series for this outcome and comparison. Applicability to the stated group: A specific heavily loaded march. Possible publication bias: No data for a separate downgrade. Study methods: Full dosing regimen and analysis unavailable in the abstract.

No advantage in squats after the march was found.

Study findings. No advantage in squats after the march was found.

Studied regimenOral choline citrate, 8.425 g as described by the source, before and during exerciseOral choline citrate, 8.425 g as described by the source, before and during exercise
Duration and populationOne march in each phase14 participants, 4 h walking at 5.6 km/h with a 34.1 kg load, 3% incline

Comparison: Placebo in a crossover protocol

Upper-body isometric strength1/4 Very lowRead moreCollapse
Confidence
1/4 Very lowPrecision of the estimate: 12 per group, large SDs and no CIs for pairwise contrasts. Consistency of results: No comparable independent series for this outcome and comparison. Applicability to the stated group: A laboratory measure in a narrow group of young men. Possible publication bias: No data for a separate downgrade. Study methods: Several tests and comparisons, small group for each dose.

No difference in upper-body isometric strength was found between the four groups.

Study findings. No difference in upper-body isometric strength was found between the four groups.

Studied regimenOral α-GPC 250 or 500 mg/dayOral α-GPC 250 or 500 mg/day
Duration and population7 days48 young men, four groups of 12

Comparison: Placebo, caffeine in a separate group

Lower-body isometric strength1/4 Very lowRead moreCollapse
Confidence
1/4 Very lowPrecision of the estimate: 12 per group, large SDs and no CIs for pairwise contrasts. Consistency of results: No comparable independent series for this outcome and comparison. Applicability to the stated group: A laboratory measure in a narrow group of young men. Possible publication bias: No data for a separate downgrade. Study methods: Several tests and comparisons, small group for each dose.

No advantage of α-GPC over placebo in lower-body isometric strength was found; caffeine was assessed separately.

Study findings. No advantage of α-GPC over placebo in lower-body isometric strength was found; caffeine was assessed separately.

Studied regimenOral α-GPC 250 or 500 mg/dayOral α-GPC 250 or 500 mg/day
Duration and population7 days48 young men, four groups of 12

Comparison: Placebo, caffeine in a separate group

Psychomotor vigilance1/4 Very lowRead moreCollapse
Confidence
1/4 Very lowPrecision of the estimate: 12 per group, large SDs and no CIs for pairwise contrasts. Consistency of results: No comparable independent series for this outcome and comparison. Applicability to the stated group: A laboratory measure in a narrow group of young men. Possible publication bias: No data for a separate downgrade. Study methods: Several tests and comparisons, small group for each dose.

No between-group difference in psychomotor vigilance was found.

Study findings. No between-group difference in psychomotor vigilance was found.

Studied regimenOral α-GPC 250 or 500 mg/dayOral α-GPC 250 or 500 mg/day
Duration and population7 days48 young men, four groups of 12

Comparison: Placebo, caffeine in a separate group

infant memory1/4 Very lowRead moreCollapse
Confidence
1/4 Very lowPrecision of the estimate: small sample, attrition or wide interval Consistency of results: no substantial grounds for downgrading established. Applicability to the stated group: indirect applicability to the general population, form or clinical outcome Possible publication bias: no substantial grounds for downgrading established. Study methods: study method and possible bias

Infant memory at 10 and 12 months showed no advantage over placebo.

Study findings. Infant memory at 10 and 12 months showed no advantage over placebo.

Studied regimen750 mg of choline a day as phosphatidylcholineoral phosphatidylcholine
Duration and populationFrom pregnancy week 18 until 90 days after birth; children assessed at 10 and 12 months140 pregnant women randomised, 99 infants assessed alongside moderate dietary choline intake (about 360 mg/day)

Comparison: placebo, corn oil

infant language development1/4 Very lowRead moreCollapse
Confidence
1/4 Very lowPrecision of the estimate: small sample, attrition or wide interval Consistency of results: no substantial grounds for downgrading established. Applicability to the stated group: indirect applicability to the general population, form or clinical outcome Possible publication bias: no substantial grounds for downgrading established. Study methods: study method and possible bias

Infant language development at 10 and 12 months showed no advantage over placebo.

Study findings. Infant language development at 10 and 12 months showed no advantage over placebo.

Studied regimen750 mg of choline a day as phosphatidylcholineoral phosphatidylcholine
Duration and populationFrom pregnancy week 18 until 90 days after birth; children assessed at 10 and 12 months140 pregnant women randomised, 99 infants assessed alongside moderate dietary choline intake (about 360 mg/day)

Comparison: placebo, corn oil

infant overall development1/4 Very lowRead moreCollapse
Confidence
1/4 Very lowPrecision of the estimate: small sample, attrition or wide interval Consistency of results: no substantial grounds for downgrading established. Applicability to the stated group: indirect applicability to the general population, form or clinical outcome Possible publication bias: no substantial grounds for downgrading established. Study methods: study method and possible bias

Infant overall development at 10 and 12 months showed no advantage over placebo.

Study findings. Infant overall development at 10 and 12 months showed no advantage over placebo.

Studied regimen750 mg of choline a day as phosphatidylcholineoral phosphatidylcholine
Duration and populationFrom pregnancy week 18 until 90 days after birth; children assessed at 10 and 12 months140 pregnant women randomised, 99 infants assessed alongside moderate dietary choline intake (about 360 mg/day)

Comparison: placebo, corn oil

CBCL social withdrawal, second primary outcome1/4 Very lowRead moreCollapse
Confidence
1/4 Very lowPrecision of the estimate: small sample, attrition or wide interval Consistency of results: no substantial grounds for downgrading established. Applicability to the stated group: indirect applicability to the general population, form or clinical outcome Possible publication bias: no substantial grounds for downgrading established. Study methods: study method and possible bias

Parents reported multiple or persistent signs of social withdrawal less often in children in the phosphatidylcholine group.

Study findings. Parents reported multiple or persistent signs of social withdrawal less often in children in the phosphatidylcholine group.

Studied regimen9000 mg of phosphatidylcholine/dayoral phosphatidylcholine
Duration and populationfrom pregnancy week 16 until delivery; children aged 18 months–4 years206 pregnant women randomised, 142 children with parent ratings

Comparison: placebo

overall WPPSI-IV IQ1/4 Very lowRead moreCollapse
Confidence
1/4 Very lowPrecision of the estimate: small sample, attrition or wide interval Consistency of results: no substantial grounds for downgrading established. Applicability to the stated group: indirect applicability to the general population, form or clinical outcome Possible publication bias: no substantial grounds for downgrading established. Study methods: study method and possible bias

Children's secondary overall IQ score was on average 7.78 points higher than in the placebo group.

Study findings. Children's secondary overall IQ score was on average 7.78 points higher than in the placebo group.

Studied regimen9000 mg of phosphatidylcholine/dayoral phosphatidylcholine
Duration and populationfrom pregnancy week 16 until delivery; assessment up to age 4children of a subset of the 206 randomised pregnant women; secondary outcome

Comparison: placebo

Acute mood1/4 Very lowRead moreCollapse
Confidence
1/4 Very lowPrecision of the estimate: Small sample, exact CI of the contrast not provided. Consistency of results: No comparable independent series for this outcome and comparison. Applicability to the stated group: Single dose and brief self-rating. Possible publication bias: No data for a separate downgrade. Study methods: Analysis df=27 with 37 experiment completers, exact set incomplete.

Self-rated mood after a single dose did not differ between groups.

Study findings. Self-rated mood after a single dose did not differ between groups.

Studied regimenOral choline bitartrate 2.5 g (about 1 g of choline) in 400 ml of orange juiceOral choline bitartrate 2.5 g (about 1 g of choline) in 400 ml of orange juice
Duration and populationSingle dose in each phase at weekly intervalsHealthy adults aged 18–29, 40 started experiment 3, 37 completed

Comparison: Cellulose 2.5 g in the same juice

Acute arousal1/4 Very lowRead moreCollapse
Confidence
1/4 Very lowPrecision of the estimate: Small sample, exact CI of the contrast not provided. Consistency of results: No comparable independent series for this outcome and comparison. Applicability to the stated group: Single dose and brief self-rating. Possible publication bias: No data for a separate downgrade. Study methods: Analysis df=27 with 37 experiment completers, exact set incomplete.

Self-rated arousal after a single dose did not differ between groups.

Study findings. Self-rated arousal after a single dose did not differ between groups.

Studied regimenOral choline bitartrate 2.5 g (about 1 g of choline) in 400 ml of orange juiceOral choline bitartrate 2.5 g (about 1 g of choline) in 400 ml of orange juice
Duration and populationSingle dose in each phase at weekly intervalsHealthy adults aged 18–29, 40 started experiment 3, 37 completed

Comparison: Cellulose 2.5 g in the same juice

Self-rated sleep1/4 Very lowRead moreCollapse
Confidence
1/4 Very lowPrecision of the estimate: 45 analysed, CI of the between-group effect not extracted. Consistency of results: No comparable independent series for this outcome and comparison. Applicability to the stated group: Sample without marked sleep disorders, clinical anxiety not studied. Possible publication bias: No data for a separate downgrade. Study methods: Secondary self-ratings, marked baseline imbalance for calmness.

No advantage in self-rated sleep was found over eight weeks.

Study findings. No advantage in self-rated sleep was found over eight weeks.

Studied regimenOral lysolecithin, 480 mg of lysophosphatidylcholine a dayOral lysolecithin, 480 mg of lysophosphatidylcholine a day
Duration and population8 weeks46 adults aged 40–74, analysis 23 and 22

Comparison: Placebo

Self-rated calmness1/4 Very lowRead moreCollapse
Confidence
1/4 Very lowPrecision of the estimate: 45 analysed, CI of the between-group effect not extracted. Consistency of results: No comparable independent series for this outcome and comparison. Applicability to the stated group: Sample without marked sleep disorders, clinical anxiety not studied. Possible publication bias: No data for a separate downgrade. Study methods: Secondary self-ratings, marked baseline imbalance for calmness.

No advantage in self-rated calmness was found by the end of week eight.

Study findings. No advantage in self-rated calmness was found by the end of week eight.

Studied regimenOral lysolecithin, 480 mg of lysophosphatidylcholine a dayOral lysolecithin, 480 mg of lysophosphatidylcholine a day
Duration and population8 weeks46 adults aged 40–74, analysis 23 and 22

Comparison: Placebo

Attention problems in children after prenatal intake1/4 Very lowRead moreCollapse
Confidence
1/4 Very lowrisk_of_bias: 64 of 206 randomised absent from the CBCL set, possible selection. inconsistency: No comparable independent series for this outcome and comparison. indirectness: A specific prenatal regimen and parent scale, without transfer to a diagnosis. imprecision: No exact CI, 142 children assessed. publication_bias: No data for a separate downgrade.

The primary attention-scale analysis found no advantage.

Study findings. The primary attention-scale analysis found no advantage.

Studied regimenOral phosphatidylcholine 9000 mg/dayOral phosphatidylcholine 9000 mg/day
Duration and populationFrom week 16 until delivery, child assessment at 18 months–4 years206 randomised pregnant women, 142 children assessed by CBCL at 18 months–4 years

Comparison: Placebo

Jump power: comparison of two α-GPC doses1/4 Very lowRead moreCollapse
Confidence
1/4 Very lowrisk_of_bias: Several tests and comparisons, small group for each dose. inconsistency: No comparable independent series for this outcome and comparison. indirectness: A laboratory measure in a narrow group of young men. imprecision: 12 per group, large SDs and no CIs for pairwise contrasts. publication_bias: No data for a separate downgrade.

A difference in power was found between two doses.

Study findings. A difference in power was found between two doses.

Studied regimenOral α-GPC 250 or 500 mg/dayOral α-GPC 250 or 500 mg/day
Duration and population7 days48 young men, four groups of 12

Comparison: 250 mg versus 500 mg, placebo and caffeine in separate groups

Safety and limitations

After a single 1000 mg dose of choline bitartrate, plasma TMAO was 12.5±10.7 versus 3.1±1.6 µmol/L with placebo in 20 adults; this is a biomarker, not a measured cardiac outcome. Over 4 weeks on 1000 mg of choline bitartrate, TMAO rose from 3.68 to 8.59 µmol/L versus 3.85 to 5.00 with placebo in 23 adults; p=0.006 concerns the change from baseline on choline. In a Korean insurance cohort of people aged 50 and over, α-GPC prescription was associated with higher stroke incidence: matched HR 1.43 (95% CI 1.41–1.46). This observational study does not prove causation and does not automatically apply to every choline form. High total choline intake may cause fishy body odour, vomiting, sweating, low blood pressure and liver injury. The adult UL of 3500 mg/day concerns food and supplements combined, not one supplement's dose. NIH ODS lists no established clinically significant drug interactions for choline itself; safety of specific derivatives is assessed separately.

Gut Microbiota-Generated Trimethylamine N-Oxide from Dietary Choline and Glucose Homeostasis in Humans ↗ · Association of L-α Glycerylphosphorylcholine With Subsequent Stroke Risk After 10 Years ↗ · NIH ODS Choline Fact Sheet for Health Professionals ↗

Food sources

The table shows total choline in the edible portion of the stated food. Weights were chosen for comparison; choline amounts and calories were calculated from one USDA record per 100 g. Total choline is not the weight of phosphatidylcholine or lecithin. USDA SR28 reference data date from 2015.

Meat and offal

Sources include meat and liver.

NIH ODS Choline Fact Sheet for Health Professionals ↗

Fish and dairy products

Choline comes from fish, milk and yoghurt.

NIH ODS Choline Fact Sheet for Health Professionals ↗

Legumes and vegetables

Choline is found in soybeans, beans, lentils and vegetables.

NIH ODS Choline Fact Sheet for Health Professionals ↗

Nuts, seeds and whole grains

Choline is also found in nuts, seeds and whole-grain products.

NIH ODS Choline Fact Sheet for Health Professionals ↗

Food composition

FoodGroupAmountServingCaloriesSources
Chicken eggwhole, hard-boiled, edible portionEggs293.8 mg of total choline / 100 g50 g · 146.9 mg of total choline · 77.5 kcalSelected comparison weight of the edible portion; values calculated from data per 100 g.155 kcal / 100 gUSDA National Nutrient Database for Standard Reference, Release 28 (2015) — food group 01 ↗
Beef liverbraised, edible portionOffal426 mg of total choline / 100 g85 g · 362.1 mg of total choline · 162.35 kcalSelected comparison weight of the edible portion; values calculated from data per 100 g.191 kcal / 100 gUSDA National Nutrient Database for Standard Reference, Release 28 (2015) — food group 13 ↗
Pork tenderloinroasted, separable lean meatMeat88.9 mg of total choline / 100 g85 g · 75.565 mg of total choline · 121.55 kcalSelected comparison weight of the edible portion; values calculated from data per 100 g.143 kcal / 100 gUSDA National Nutrient Database for Standard Reference, Release 28 (2015) — food group 10 ↗
Sockeye salmoncooked with dry heatFish112.6 mg of total choline / 100 g85 g · 95.71 mg of total choline · 132.6 kcalSelected comparison weight of the edible portion; values calculated from data per 100 g.156 kcal / 100 gUSDA National Nutrient Database for Standard Reference, Release 28 (2015) — food group 15 ↗
Atlantic codcooked with dry heatFish83.7 mg of total choline / 100 g85 g · 71.145 mg of total choline · 89.25 kcalSelected comparison weight of the edible portion; values calculated from data per 100 g.105 kcal / 100 gUSDA National Nutrient Database for Standard Reference, Release 28 (2015) — food group 15 ↗
Milkwhole, 3.25% fat, without added vitamins A and DDairy products14.3 mg of total choline / 100 g200 g · 28.6 mg of total choline · 122 kcalSelected comparison weight of the edible portion; values calculated from data per 100 g.61 kcal / 100 gUSDA National Nutrient Database for Standard Reference, Release 28 (2015) — food group 01 ↗
Yoghurtplain, low-fat, 12 g of protein per 8 ouncesDairy products15.2 mg of total choline / 100 g170 g · 25.84 mg of total choline · 107.1 kcalSelected comparison weight of the edible portion; values calculated from data per 100 g.63 kcal / 100 gUSDA National Nutrient Database for Standard Reference, Release 28 (2015) — food group 01 ↗
Soybeansmature, boiled, without saltLegumes47.5 mg of total choline / 100 g100 g · 47.5 mg of total choline · 172 kcalSelected comparison weight of the edible portion; values calculated from data per 100 g.172 kcal / 100 gUSDA National Nutrient Database for Standard Reference, Release 28 (2015) — food group 16 ↗
Black beansmature, boiled, without saltLegumes32.6 mg of total choline / 100 g100 g · 32.6 mg of total choline · 132 kcalSelected comparison weight of the edible portion; values calculated from data per 100 g.132 kcal / 100 gUSDA National Nutrient Database for Standard Reference, Release 28 (2015) — food group 16 ↗
Lentilsmature, boiled, without saltLegumes32.7 mg of total choline / 100 g100 g · 32.7 mg of total choline · 116 kcalSelected comparison weight of the edible portion; values calculated from data per 100 g.116 kcal / 100 gUSDA National Nutrient Database for Standard Reference, Release 28 (2015) — food group 16 ↗
Broccoliboiled, drained, without saltVegetables40.1 mg of total choline / 100 g78 g · 31.278 mg of total choline · 27.3 kcalSelected comparison weight of the edible portion; values calculated from data per 100 g.35 kcal / 100 gUSDA National Nutrient Database for Standard Reference, Release 28 (2015) — food group 11 ↗
Brussels sproutsboiled, drained, without saltVegetables40.6 mg of total choline / 100 g78 g · 31.668 mg of total choline · 28.08 kcalSelected comparison weight of the edible portion; values calculated from data per 100 g.36 kcal / 100 gUSDA National Nutrient Database for Standard Reference, Release 28 (2015) — food group 11 ↗
Almondsdry-roasted, without added saltNuts and seeds52.1 mg of total choline / 100 g30 g · 15.63 mg of total choline · 179.4 kcalSelected comparison weight of the edible portion; values calculated from data per 100 g.598 kcal / 100 gUSDA National Nutrient Database for Standard Reference, Release 28 (2015) — food group 12 ↗
Sunflower seedsdry-roasted kernels, without saltNuts and seeds55.1 mg of total choline / 100 g30 g · 16.53 mg of total choline · 174.6 kcalSelected comparison weight of the edible portion; values calculated from data per 100 g.582 kcal / 100 gUSDA National Nutrient Database for Standard Reference, Release 28 (2015) — food group 12 ↗
Oatmealunenriched flakes, cooked in water without saltWhole-grain products7.4 mg of total choline / 100 g200 g · 14.8 mg of total choline · 142 kcalSelected comparison weight of the edible portion; values calculated from data per 100 g.71 kcal / 100 gUSDA National Nutrient Database for Standard Reference, Release 28 (2015) — food group 08 ↗

Studies

PublicationWhat was studiedParticipantsForm and doseResult
No Acute Effects of Choline Bitartrate Food Supplements on Memory in Healthy, Young, Human Adults ↗Spatial working memory: Spatial working memory Declarative recall: Declarative recall Verbal working memory: Verbal working memory Acute mood: Acute mood Acute arousal: Acute arousalSpatial working memory: Healthy adults aged 18–29, 40 started experiment 3, 37 completed Declarative recall: Healthy adults aged 18–29, 40 started experiment 3, 37 completed Verbal working memory: Healthy adults aged 18–29, 40 started experiment 3, 37 completed Acute mood: Healthy adults aged 18–29, 40 started experiment 3, 37 completed Acute arousal: Healthy adults aged 18–29, 40 started experiment 3, 37 completedSpatial working memory: Oral choline bitartrate 2.5 g (about 1 g of choline) in 400 ml of orange juice; Oral choline bitartrate 2.5 g (about 1 g of choline) in 400 ml of orange juice; Single dose in each phase, 1-week interval; comparison: Placebo Declarative recall: Oral choline bitartrate 2.5 g (about 1 g of choline) in 400 ml of orange juice; Oral choline bitartrate 2.5 g (about 1 g of choline) in 400 ml of orange juice; Single dose in each phase, 1-week interval; comparison: Placebo Verbal working memory: Oral choline bitartrate 2.5 g (about 1 g of choline) in 400 ml of orange juice; Oral choline bitartrate 2.5 g (about 1 g of choline) in 400 ml of orange juice; Single dose in each phase, 1-week interval; comparison: Placebo Acute mood: Oral choline bitartrate 2.5 g (about 1 g of choline) in 400 ml of orange juice; Oral choline bitartrate 2.5 g (about 1 g of choline) in 400 ml of orange juice; Single dose in each phase at weekly intervals; comparison: Cellulose 2.5 g in the same juice Acute arousal: Oral choline bitartrate 2.5 g (about 1 g of choline) in 400 ml of orange juice; Oral choline bitartrate 2.5 g (about 1 g of choline) in 400 ml of orange juice; Single dose in each phase at weekly intervals; comparison: Cellulose 2.5 g in the same juiceSpatial working memory: A single dose of choline bitartrate showed no advantage in spatial working memory. Declarative recall: A single dose of choline bitartrate showed no advantage in declarative recall. Verbal working memory: A single dose of choline bitartrate showed no advantage in verbal working memory. Acute mood: Self-rated mood after a single dose did not differ between groups. Acute arousal: Self-rated arousal after a single dose did not differ between groups.
Effects of an 8-week intake of lysolecithin on cognitive function and concentrations of blood choline and lysophosphatidylcholine: a randomized, double-blinded, placebo-controlled trial ↗Overall WMS-R memory: Overall WMS-R memory Self-rated sleep: Self-rated sleep Self-rated calmness: Self-rated calmnessOverall WMS-R memory: 46 adults aged 40–74, analysis 23 and 22 Self-rated sleep: 46 adults aged 40–74, analysis 23 and 22 Self-rated calmness: 46 adults aged 40–74, analysis 23 and 22Overall WMS-R memory: Oral lysolecithin, 480 mg of lysophosphatidylcholine a day; Oral lysolecithin, 480 mg of lysophosphatidylcholine a day; 8 weeks; comparison: Placebo Self-rated sleep: Oral lysolecithin, 480 mg of lysophosphatidylcholine a day; Oral lysolecithin, 480 mg of lysophosphatidylcholine a day; 8 weeks; comparison: Placebo Self-rated calmness: Oral lysolecithin, 480 mg of lysophosphatidylcholine a day; Oral lysolecithin, 480 mg of lysophosphatidylcholine a day; 8 weeks; comparison: PlaceboOverall WMS-R memory: Lysolecithin showed no advantage in overall memory over eight weeks. Self-rated sleep: No advantage in self-rated sleep was found over eight weeks. Self-rated calmness: No advantage in self-rated calmness was found by the end of week eight.

Sources

Sources
  1. No Acute Effects of Choline Bitartrate Food Supplements on Memory in Healthy, Young, Human Adults ↗
  2. Effects of an 8-week intake of lysolecithin on cognitive function and concentrations of blood choline and lysophosphatidylcholine: a randomized, double-blinded, placebo-controlled trial ↗
  3. Citicoline and Memory Function in Healthy Older Adults: A Randomized, Double-Blind, Placebo-Controlled Clinical Trial ↗
  4. Effect of choline supplementation on fatigue in trained cyclists ↗
  5. The effects of choline supplementation on physical performance ↗
  6. Evaluation of the effects of two doses of alpha glycerylphosphorylcholine on physical and psychomotor performance ↗
  7. Phosphatidylcholine supplementation in pregnant women consuming moderate-choline diets does not enhance infant cognitive function: a randomized, double-blind, placebo-controlled trial ↗
  8. Prenatal Maternal Phosphatidylcholine and Children's Behavior and Cognition through 4 Years of Age: Randomized Clinical Trial ↗
  9. Gut Microbiota-Generated Trimethylamine N-Oxide from Dietary Choline and Glucose Homeostasis in Humans ↗
  10. Association of L-α Glycerylphosphorylcholine With Subsequent Stroke Risk After 10 Years ↗
  11. NIH ODS Choline Fact Sheet for Health Professionals ↗
  12. USDA National Nutrient Database for Standard Reference, Release 28 (2015) — food group 01 ↗
  13. USDA National Nutrient Database for Standard Reference, Release 28 (2015) — food group 13 ↗
  14. USDA National Nutrient Database for Standard Reference, Release 28 (2015) — food group 10 ↗
  15. USDA National Nutrient Database for Standard Reference, Release 28 (2015) — food group 15 ↗
  16. USDA National Nutrient Database for Standard Reference, Release 28 (2015) — food group 16 ↗
  17. USDA National Nutrient Database for Standard Reference, Release 28 (2015) — food group 11 ↗
  18. USDA National Nutrient Database for Standard Reference, Release 28 (2015) — food group 12 ↗
  19. USDA National Nutrient Database for Standard Reference, Release 28 (2015) — food group 08 ↗